Foundation Medicine Receives New Coverage from Analysts at Tigress Financial (FMI)
Tigress Financial initiated coverage on shares of Foundation Medicine (NYSE:FMI) in a research note issued on Friday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating on the stock.
In other Foundation Medicine news, COO Steven J. Kafka unloaded 10,000 shares of the stock in a transaction that occurred on Tuesday, July 22nd. The shares were sold at an average price of $27.14, for a total transaction of $271,400.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Foundation Medicine (NYSE:FMI) opened at 22.23 on Friday. Foundation Medicine has a 1-year low of $19.513 and a 1-year high of $45.00. The stock has a 50-day moving average of $25.56 and a 200-day moving average of $28.68. The company’s market cap is $626.7 million.
Foundation Medicine (NYSE:FMI) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.48) by $0.04. The company had revenue of $11.45 million for the quarter, compared to the consensus estimate of $11.33 million. The company’s quarterly revenue was up 120.2% on a year-over-year basis. On average, analysts predict that Foundation Medicine will post $-1.82 earnings per share for the current fiscal year.
FMI has been the subject of a number of other recent research reports. Analysts at Janney Montgomery Scott initiated coverage on shares of Foundation Medicine in a research note on Wednesday, June 25th. They set a “neutral” rating and a $28.00 price target on the stock. Analysts at Leerink Swann cut their price target on shares of Foundation Medicine from $36.00 to $33.00 in a research note on Friday, May 9th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $38.80.
Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.